19th Mar 2021 10:29
(Alliance News) -Â Oxford Biomedica PLC on Friday said Sanofi SA intends to terminate the collaboration and license agreement between the two firms in the field of haemophilia gene therapy.
Oxford Biomedica had originally signed the pact for process development and manufacturing of lentiviral vectors to treat haemophilia with Bioverativ, which was acquired by French pharmaceutical firm Sanofi, in February 2018.
"The group expects that the impact on revenue will be negligible over the coming 24 month period," Oxford Biomedica said.
Shares in gene and cell therapy company Oxford Biomedica were down 2.7% at 994.00 pence in London on Friday.
By Lucy Heming;Â [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica